Compare KD & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | IRON |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2021 | 2020 |
| Metric | KD | IRON |
|---|---|---|
| Price | $11.28 | $68.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $25.92 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 3.6M | 439.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $15,092,000,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $0.08 | $283.52 |
| P/E Ratio | $13.24 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $10.10 | $40.00 |
| 52 Week High | $43.74 | $99.50 |
| Indicator | KD | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 50.91 |
| Support Level | $11.11 | $64.39 |
| Resistance Level | $13.81 | $71.85 |
| Average True Range (ATR) | 0.52 | 3.10 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 10.84 | 48.13 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.